Cargando…
A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222
In the era of globally predominant omicron strains, a COVID-19 booster vaccine is needed. Our study aimed to evaluate the immunogenicity of a half-dose BNT162b2 booster after AZD1222 in healthy adults. A randomized trial of volunteers aged 18–69 years who received two-dose AZD1222 was conducted. The...
Autores principales: | Nantanee, Rapisa, Jantarabenjakul, Watsamon, Jaru-Ampornpan, Peera, Sodsai, Pimpayao, Himananto, Orawan, Athipunjapong, Jitthiwa, Sophonphan, Jiratchaya, Nanthapisal, Sira, Hirankarn, Nattiya, Puthanakit, Thanyawee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230769/ https://www.ncbi.nlm.nih.gov/pubmed/35746522 http://dx.doi.org/10.3390/vaccines10060914 |
Ejemplares similares
-
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
por: Nanthapisal, Sira, et al.
Publicado: (2022) -
Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac
por: Nantanee, Rapisa, et al.
Publicado: (2022) -
Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents
por: Puthanakit, Thanyawee, et al.
Publicado: (2022) -
Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
por: Puthanakit, Thanyawee, et al.
Publicado: (2022) -
Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance
por: Nantanee, Rapisa, et al.
Publicado: (2023)